Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Eyepoint Pharmaceuticals Inc (EYPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Eyepoint Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.970 -0.660    -3.74%
17:25:20 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 132,917
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 16.970 - 18.040
Type:  Equity
Market:  United States
Eyepoint Pharma 16.970 -0.660 -3.74%

Eyepoint Pharma Company Profile

 
Read the pSivida company profile to learn more about the business and the management team. View Eyepoint Pharmaceuticals Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

121

Equity Type

ORD

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Contact Information

Address 480 Pleasant Street Suite A-210
Watertown, 02472
United States
Phone 617 926 5000
Fax 617 926 5050

Top Executives

Name Age Since Title
Goran A. Ando 74 2018 Independent Non-Executive Chairman
Jay S. Duker 64 2020 President, CEO & Director
Nancy S. Lurker 66 2016 Executive Vice-Chairman
Anat Loewenstein - 2023 Member of Executive Scientific Advisory Board
Anthony P. Adamis 64 2022 Independent Director
Karen Zaderej 61 2022 Independent Director
Stuart Duty 58 2023 Independent Director
Wendy F. DiCicco 57 2019 Independent Director
David Robert Guyer 64 2019 Independent Director
Charles C. Wykoff - 2021 Co-Chair of Scientific Advisory Board
Rishi P. Singh - 2021 Member of Executive Scientific Advisory Board
Glenn J. Jaffe - 2021 Member of Executive Scientific Advisory Board
Allen C. Ho - 2024 Member of Scientific Advisory Board
David S. Boyer - 2021 Member of Executive Scientific Advisory Board
Carl D. Regillo - 2021 Co- Chairman of Scientific Advisory Board
Anna Kluczewska - - CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd
Ye Liu 52 2020 Director
Sophie J. Bakri - 2021 Member of Executive Scientific Advisory Board
Usha Chakravarthy - 2024 Member of Scientific Advisory Board
Frank G. Holz - 2024 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EYPT Price Commentary

Write your thoughts about Eyepoint Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email